- Home
- OPP vs WHWK Comparison
OPP vs WHWK Comparison
Compare OPP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.19
Company Overview
Basic Information| Metric | OPP | WHWK |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 196.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPP | WHWK |
|---|---|---|
| Price | $7.82 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 89.8K | ★ 223.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.49 | $1.44 |
| 52 Week High | $8.77 | $4.40 |
Technical Indicators
Market Signals| Indicator | OPP | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 61.28 |
| Support Level | $7.49 | $1.84 |
| Resistance Level | $8.00 | $4.40 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 51.83 | 80.09 |
Price Performance
Historical Comparison OPP
WHWK
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.